When a pharmaceutical company reveals information about success in a clinical trial of one of its products, then it almost always has a positive effect on the stock price. That is what happened with CVM stock after Cel-Sci Corporation (NYSEAMERICAN:CVM) announced results from the clinical trial of its product Multikine, which is a form of leukocyte interleukin injection.
CVM Stock Gains Further MomentumAccording to the information released by the company, the product managed to reach the primary endpoint meant to indicate overall survival. It goes without saying that it is an important development and CVM ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.